Neuland Laboratories Limited

Neuland Labs Announces Special Window for Share Transfer and Dematerialization

Neuland Laboratories Limited has opened a Special Window for transfer and dematerialization of physical shares, as per SEBI guidelines. Advertisements were published on March 11, 2026. For FY25, revenue was ₹5,06,290.45 lakh and Q4 FY25 revenue was ₹1,75,960.56 lakh. A dividend of ₹21 per share was declared for FY24.

Neuland Labs to Participate in Analyst/Investor Meetings in HK & Singapore

Neuland Laboratories Limited management will attend a non-deal roadshow by B&K Securities. Meetings are scheduled in Hongkong on March 10, 2026, and in Singapore on March 11-12, 2026. The schedule is subject to change.

Neuland Labs Director Dr. Christopher M Cimarusti Passes Away

Dr. Christopher M Cimarusti, a Non-Executive Non-Independent Director of Neuland Laboratories Limited, passed away on February 28, 2026. He had been on the board since 2009 and was instrumental in the company's R&D functions.

Neuland Labs Q3 FY26 Earnings Call Transcript Released

Neuland Laboratories released its Q3 FY26 earnings call transcript. Total income rose 11.4% YoY to ₹447.8 crores. EBITDA was ₹85 crores (19% margin), impacted by INR 10 crores in labor code expenses. Capex for 9MFY26 was ₹254 crores. The company is focusing on long-term growth and strategic shifts in its CDMO business.

Neuland Labs: NIL transfer requests re-lodged for physical shares in Jan 2026

Neuland Laboratories Limited reported nil re-lodgement of transfer requests for physical shares in January 2026. This update complies with SEBI's circular dated July 2, 2025, and no requests were processed or approved.

Neuland Labs Announces Newspaper Publication of Q3 FY26 Financial Results

Neuland Laboratories Limited published its financial results for the quarter and nine months ended December 31, 2025, on February 10, 2026. The company is undertaking a significant expansion with a new manufacturing block at Pashamylaram, Hyderabad, costing ₹500 crore. Additionally, capacity will be expanded by 250,000 sq ft across existing sites.

Neuland Labs: Audio Recording of Q3 FY26 Earnings Call Available

Neuland Laboratories Limited has released the audio recording of their earnings call for the quarter and nine months ended December 31, 2025. The call took place on February 9, 2026. The recording is accessible on the company's website.

Neuland Labs Q3FY26 Investor Presentation Highlights

Neuland Laboratories reported Q3FY26 Total Income of ₹447.8 crore (up 11.4% YoY), but PAT declined 60% YoY to ₹40.4 crore. EBITDA was ₹85 crore, with margins at 19.0%. For 9MFY26, Total Income was ₹1264.4 crore, and PAT was ₹150.6 crore. The company approved moving its R&D to a 140k sq ft facility and had a Capex outflow of ₹254 crore in 9MFY26.

Neuland Labs Q3FY26 Revenue at ₹447.8 Cr, EBITDA Declines 5.9% YoY

Neuland Laboratories reported Q3FY26 total income of ₹447.8 crore, up 11.4% YoY. EBITDA was ₹85.0 crore, down 5.9% YoY, with margins at 19.0%. PAT stood at ₹40.4 crore, a 60.2% decrease. Management cited product mix and operating expenses for subdued margins, while highlighting long-term investments and growing customer interest.

Neuland Labs Q3FY26 Results: Revenue at ₹439.7 Cr, Profit ₹40.5 Cr

Neuland Laboratories Limited reported unaudited results for Q3FY26. Consolidated revenue was ₹447.71 crore and profit after tax was ₹40.57 crore. For the nine-month period, revenue stood at ₹1,264.44 crore with a profit after tax of ₹151.33 crore. The results were approved by the Board on February 9, 2026.

Neuland Labs to Participate in Nuvama India Conference 2026 on Feb 11

Neuland Laboratories Limited management will attend the Nuvama India Conference 2026 in Mumbai on February 11, 2026. The event will include group meetings and one-on-one sessions with analysts and institutional investors.

Neuland Labs: Statutory Auditors M S K A & Associates Convert to LLP

Neuland Laboratories Limited's statutory auditors, M S K A & Associates, have converted to a Limited Liability Partnership (LLP) effective January 13, 2026. The firm is now known as M S K A & Associates LLP. This change in constitution does not alter the audit engagement or their tenure.

Neuland Labs to announce Q3 FY26 results on Feb 09, 2026, followed by earnings call.

Neuland Laboratories Limited will announce its Q3 FY26 results on February 09, 2026. The company will host an earnings call on the same day at 17:30 hrs IST to discuss the financial performance.

Neuland Labs Files SEBI Compliance Certificate for Q3 FY26

Neuland Laboratories Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending December 31, 2025. The company's Registrar and Share Transfer Agent, Kfin Technologies Limited, provided the details of securities dematerialized/rematerialized. The filing was made on January 2, 2026.

Neuland Labs: No Physical Share Transfer Requests Re-lodged in Dec 2025

Neuland Laboratories Limited reported that as of December 31, 2025, there were no re-lodgement requests for physical share transfers processed in December. This update is in line with SEBI's circular regarding a special window for physical share transfers.

Neuland Labs: Trading Window Closed Jan 1, 2026 for Q3 FY26 Results

Neuland Laboratories Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and nine months ended December 31, 2025. The board meeting date for results declaration will be announced later.

Neuland Labs Announces Special Window for Physical Share Transfer Re-lodgement

Neuland Laboratories Limited announced a Special Window for re-lodgement of transfer requests for physical shares. This initiative is in compliance with SEBI regulations and was advertised on December 19, 2025, in Financial Express and Nava Telangana.

Neuland Labs to Participate in Analyst/Institutional Investor Meeting on Dec 18

Neuland Laboratories Limited management will attend a group analyst/investor meeting with B&K Securities on December 18, 2025, in Hyderabad. This event is part of a non-deal roadshow and may involve one-on-one discussions.

Cancellation of Analyst/Institutional Investor Meeting Scheduled on December 10, 2025

Neuland Laboratories Limited cancelled its Analyst/Institutional Investor Meeting with B&K Securities, previously scheduled for December 10, 2025, in Hyderabad.

Re-lodgement of Transfer Requests of Physical Shares

Neuland Laboratories Limited announces updates on the re-lodgement of physical share transfer requests as of November 30, 2025, in compliance with SEBI circular dated July 2, 2025.

Neuland Laboratories to participate in Analyst/Investor Meetings

Neuland Laboratories will participate in analyst/investor meetings, including a meeting with B&K Securities in Hyderabad on December 10, 2025, for a non-deal roadshow.

Neuland Laboratories announces participation in Nuvama investor meet

Neuland Laboratories Limited to participate in analyst/investor meetings with Nuvama in Mumbai on December 4 & 5, 2025, for a non-deal roadshow.

Neuland Laboratories approves ₹189 Cr capex for new R&D Center

Neuland Laboratories approves ₹189 crore capital expenditure for setting up a new Research & Development (R&D) Center at Genome Valley, Hyderabad, to be financed through borrowings and internal accruals.

Newspaper Advertisement: Special Window for Re-lodgement of Physical Shares

Neuland Laboratories Limited announced a special window for re-lodgement of transfer requests for physical shares, advertised in Financial Express and Nava Telangana on November 26, 2025.

Re-lodgement of Transfer Requests of Physical Shares

Neuland Laboratories Limited informs about the re-lodgement of transfer requests of physical shares as per SEBI circular. No requests were received during the month ended October 31, 2025.

Neuland Laboratories Q2 FY26 Earnings Call Transcript

Neuland Laboratories announced Q2 FY26 results with a 63.7% increase in total income to ₹516 crore. EBITDA stood at ₹156.9 crore. The company expects strong growth in FY26 and commercialization of another molecule soon.

Neuland Labs publishes newspaper ads on special window for physical share transfer requests

Neuland Laboratories published newspaper ads on November 11, 2025, informing about a Special Window for re-lodgement of physical share transfer requests, complying with SEBI Regulation 47.

Neuland Laboratories reports robust Q2 FY26 results: Net Profit up over 2.9x, Total Income surges

Neuland Laboratories announced strong Q2 FY26 financial results with significant increases in total income and net profit after tax for both consolidated and standalone figures.

Neuland Laboratories releases audio recording of Q2 & H1 FY26 earnings call

Neuland Laboratories released the audio recording of its earnings call for the quarter and half year ended September 30, 2025, which was conducted on November 7, 2025.

Neuland Labs reports strong Q2FY26 standalone results with significant revenue and PAT growth

Neuland Labs reported strong Q2FY26 standalone results, with revenue up 63.7% to ₹516.1 crore and PAT up 201.6% to ₹96.5 crore, driven by CMS projects and operational improvements.

Neuland Labs Q2 FY26 Total Income at ₹516.1 crore; EBITDA up 138.8% YoY to ₹156.9 crore

Neuland Labs reported strong Q2 FY26 results with total income of ₹516.1 crore and EBITDA of ₹156.9 crore, driven by CMS projects. Management expects continued momentum and growth.

Neuland Labs Approves Unaudited Financial Results for Quarter Ended Sep 30, 2025

Neuland Laboratories Limited approved unaudited financial results for the quarter and half year ended September 30, 2025 in board meeting held on November 7, 2025.

Voting Results for Postal Ballot: Re-designation of Directors Approved

Neuland Laboratories announces the successful passing of special resolutions via postal ballot, re-designating Mr. Davuluri Sucheth Rao and Mr. Davuluri Saharsh Rao as Executive Vice Chairman and CEO & Managing Director respectively.

Neuland Labs schedules Q2 FY26 earnings call and results announcement for November 7, 2025

Neuland Laboratories Limited will announce Q2 FY26 results and host an earnings call on November 07, 2025.

Neuland Labs publishes ad for special window for physical share transfer re-lodgement

Neuland Laboratories published newspaper ads on October 25, 2025, announcing a special window for physical share transfer re-lodgement, as per SEBI regulations.

Neuland Laboratories reports NIL re-lodgement requests for physical share transfers in Sep 2025

Neuland Laboratories reported NIL re-lodgement requests for physical share transfers for the month ended September 30, 2025, as per SEBI circular. The update was provided by Kfin Technologies Limited.

Neuland Laboratories: Newspaper Advertisement for Physical Share Transfer

Neuland Laboratories Limited publicized a newspaper advertisement on October 9, 2025, concerning the special window for re-lodgement of transfer requests for physical shares.

Neuland Labs publishes newspaper ad for Postal Ballot Notice and e-voting information

Neuland Laboratories published newspaper ads on October 7, 2025, regarding the dispatch of its Postal Ballot Notice and e-voting information, in compliance with SEBI regulations.

Neuland Labs proposes re-designation of key whole-time directors via postal ballot

Neuland Labs seeks shareholder approval via postal ballot for re-designating Mr. Davuluri Sucheth Rao as Executive Vice Chairman and Mr. Davuluri Saharsh Rao as CEO & MD, effective April 1, 2026, to enhance governance and operations.

Neuland Laboratories files Regulation 74(5) certificate for Q3 2025

Neuland Laboratories filed the Regulation 74(5) certificate for the quarter ended September 30, 2025, confirming dematerialization/rematerialization details to stock exchanges via Kfin Technologies.

Shareholders approve Dr. Ravi Shankar Gopinath's appointment as Independent Director

Neuland Labs Realigns Executive Leadership for Growth, Effective April 1, 2026

Corrigendum to Postal Ballot Notice regarding Independent Director Appointment

Neuland Laboratories Announces Special Window for Physical Share Transfers

Neuland Laboratories Commences Commercial Production at Unit 3 Expansion

Neuland Laboratories Announces Postal Ballot Notice Advertisement

Neuland Labs Seeks Shareholder Approval for Dr. Ravi Shankar Gopinath as Independent Director

Neuland Labs to participate in Nuvama Non Deal Roadshow on 25 Aug 2025

Neuland Laboratories to participate in Analyst/Institutional Investor Meeting

Neuland Labs Announces Newspaper Publication of Financial Results